Patient on treatment on carbidopa + levodopa for 10 yrs now has weaning off effect. What should be added to restore action ?
**Core Concept**
Carbidopa and levodopa are used in the treatment of Parkinson's disease. Levodopa is a precursor to dopamine, and carbidopa inhibits the peripheral conversion of levodopa to dopamine, thereby increasing its availability in the brain. However, long-term treatment can lead to a weaning-off effect due to the development of tolerance.
**Why the Correct Answer is Right**
To restore the action of levodopa, a dopamine receptor agonist can be added. Dopamine receptor agonists directly stimulate dopamine receptors, bypassing the need for levodopa to cross the blood-brain barrier and convert to dopamine. This can help restore motor function and alleviate symptoms in patients with a weaning-off effect. Examples of dopamine receptor agonists include pramipexole and ropinirole.
**Why Each Wrong Option is Incorrect**
**Option A:** Adding a peripheral decarboxylase inhibitor, such as carbidopa, would not help restore the action of levodopa, as the problem lies in the central nervous system, not in the peripheral conversion of levodopa.
**Option B:** Increasing the dose of levodopa would not be effective in the long term, as it can lead to further development of tolerance and worsen side effects.
**Option C:** Adding a monoamine oxidase B (MAO-B) inhibitor, such as selegiline, can help slow the breakdown of dopamine, but it does not directly restore the action of levodopa.
**Clinical Pearl / High-Yield Fact**
When adding a dopamine receptor agonist to a patient with a weaning-off effect, it's essential to monitor for side effects such as nausea, vomiting, and orthostatic hypotension, as these medications can have a pro-dopaminergic effect.
**Correct Answer:** C. MAO-B inhibitors can be used to slow the breakdown of dopamine, but the best choice in this scenario is to add a dopamine receptor agonist.